国产重组链激酶与尿激酶在急性下肢深静脉血栓溶栓中的疗效观察

目的观察国产重组链激酶(recombinant streptokinase,r-SK)与尿激酶(urokinase,UK)在急性下肢深静脉血栓(acute deep venious thrombosis,ADVT)溶栓治疗中的临床疗效和不良反应.方法采用平行随机单盲对照试验,自2004年1月～2004年10月对50例急性下肢深静脉血栓形成患者分为2组,每组各25例,A组给予r SK50万U溶栓,B组给予UK50万U溶栓治疗,疗程5 d,总量250万U.同时加用抗凝,抗血小板药物治疗.观察疗效的临床指标、过敏反应及出血并发症等.结果国产重组链激酶组(A组)溶栓有效率为88%,尿激酶组(B组)溶栓有效率为68%,两组间有显著性差异(P＜0.05).两组的不良反应及出血均无显著性差异(P＞0.05).结论重组链激酶和尿激酶都是治疗ADVT疗效肯定、安全的溶栓药物,重组链激酶的疗效明显优于尿激酶.

COMPARATIVE STUDY ON THE EFFECTS OF RECOMBINANT STREPTOKINASE AND UROKINASE IN THE TREATMENT OF PATIENTS WITH ACUTE DEEP VENIOUS THROMBOSIS

ObjectiveTo observe and compare the clinic efficacy and adverse reaction of recombinant streptokinase(r-SK) and urokinase(UK) in the treatment of patients with acute deep venious thrombosis(ADVT).MethodsFifty patients with ADVT were randomly divided into two groups with 25 patients in each group.Patients in group A and B were respectively treated by(r-SK)((0.5) MU) and UK((0.5) MU) for 5 days,and the total of dosages were(2.5) MU.Anticoagulant and anti-platelet drugs were used at the same time.Clinical criteria of efficacy and the complication of hypersensitivity and bleeding were evaluated.ResultsThe total efficiency rate for r-SK(group A) was 88%,which was significantly higher than that of group B(UK)(P<(0.05)).There was no significant difference in the rate hemorrhage and other adverse reactions between two groups(P>(0.05)).ConclusionBoth r-SK and UK were effective,reliable and safe thrombolytic agent.However,recombinant streptokinase showed significantly better clinical efficacy than of urokinase in thrombolytic therapy.